Kinase inhibitors: Ligand-based de novo design is validated as a viable technology for rapidly generating innovative compounds possessing the desired biochemical profile. The study discloses the discovery of the most selective vascular endothelial growth factor receptor-2 (VEGFR-2) kinase inhibitor (right in scheme) known to date as prime lead for antiangiogenic drug development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/anie.201304847 | DOI Listing |
Publication Analysis
Top Keywords
steering target
4
target selectivity
4
selectivity potency
4
potency fragment-based
4
fragment-based novo
4
novo drug
4
drug design
4
design kinase
4
kinase inhibitors
4
inhibitors ligand-based
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!